Drug profile · INN
asciminib hydrochloride
SCEMBLIX
asciminib hydrochloride (SCEMBLIX) is a bcr/abl fusion protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — asciminib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 7
- Data quality
- 0.84
Quick answer
asciminib hydrochloride (SCEMBLIX) is a bcr/abl fusion protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bcr/Abl fusion protein inhibitor
Primary target: Bcr/Abl fusion protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is asciminib hydrochloride?
asciminib hydrochloride (SCEMBLIX) is a bcr/abl fusion protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for asciminib hydrochloride?
SCEMBLIX is a marketed brand name for asciminib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of asciminib hydrochloride?
asciminib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.